EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Jianxing He100 enrolled

Overview

A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC

Patients with EGFR mutation and presented secondary resistance to prior first-generation EGFR-TKI should have received biopsy of at least on progressed lesions and are able to provide tissues for pathological examination and NGS testing.All enrolled patients will be followed up to clinical outcome (treatments, tumor response, survival, etc).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Nonsmall Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Male or female patients aged 18 years and older. * Histological confirmation of stage IIIB/IV NSCLC. * Documented EGFR mutation positive . * WHO Performance Status 0, 1 or 2 Exclusion Criteria: * Any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study. * Previous (within 6 months) or current treatment with AZD9291.

Outcomes

Primary Outcomes

The biomarker profile of EGFR-TKI resistance

Time frame: Baseline

Secondary Outcomes

The concordance, sensitivity and specificity in paired blood and tissue samples

Time frame: Baseline

Central Contacts

Jian Xing HE, MD

CONTACT

86-20-83062338 yxy701@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.